Spark Investment Management’s Protalix BioTherapeutics PLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$32.6K Buy
+11,800
New +$29.4K 0.05% 117
2017
Q1
– Sell
-2,380
Closed -$10K – 874
2016
Q4
$10K Sell
2,380
-3,730
-61% -$16.7K ﹤0.01% 763
2016
Q3
$34K Sell
6,110
-1,210
-17% -$7.55K ﹤0.01% 800
2016
Q2
$46K Sell
7,320
-3,643
-33% -$29.1K ﹤0.01% 755
2016
Q1
$92K Sell
10,963
-11,997
-52% -$103K 0.01% 704
2015
Q4
$234K Buy
22,960
+19,933
+659% +$203K 0.03% 553
2015
Q3
$35K Buy
3,027
+1,407
+87% +$22.4K ﹤0.01% 656
2015
Q2
$31K Hold
1,620
– – ﹤0.01% 642
2015
Q1
$28K Sell
1,620
-6,420
-80% -$126K ﹤0.01% 693
2014
Q4
$147K Sell
8,040
-1,350
-14% -$29K 0.02% 540
2014
Q3
$227K Buy
9,390
+4,750
+102% +$137K 0.03% 494
2014
Q2
$169K Buy
+4,640
New +$187K 0.03% 511

Other funds holding PLX

Spark Investment Management's PLX Position: Q3 2026 in Review

Spark Investment Management opened a new position in Protalix BioTherapeutics (PLX) in Q3 2026: 11,800 shares worth $32.6K. The stake represents 0.05% of the portfolio and ranks #117 among its holdings. This is a return to the name: Spark Investment Management previously reported a position in PLX as recently as Q4 2016.

Spark Investment Management first reported a position in PLX in Q2 2014 and has held it in 12 quarters since. The position peaked at $234K in Q4 2015. 107 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • Spark Investment Management held 11,800 shares of Protalix BioTherapeutics worth $32.6K as of Q3 2026.
  • Protalix BioTherapeutics was a new Spark Investment Management position in Q3 2026.
  • Protalix BioTherapeutics made up 0.05% of Spark Investment Management's portfolio in Q3 2026, its #117 holding.
  • Spark Investment Management first reported a position in Protalix BioTherapeutics in Q2 2014 and has held it in 12 quarters since.
  • Spark Investment Management's Protalix BioTherapeutics position peaked at $234K in Q4 2015.
  • 107 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Spark Investment Management's 13F filing for Q3 2026, filed 13 Nov 2026.